Tag: Hemophilia a

In clinical trials, Feiba was effective in managing 88% to 93% of bleeding episodes in patients with hemophilia and inhibitors. **What is Feiba?** It is an Anti-Inhibitor Coagulant Complex used to control and prevent bleeding in these specific patient populations.

Hemophilia A is a genetic bleeding disorder that affects approximately 1 in 5,000 male births and is caused by a deficiency of clotting factor VIII. The medication **Kogenate**, a brand of recombinant Factor VIII, works by temporarily replacing this missing protein, restoring the blood's ability to clot effectively and enabling the control and prevention of bleeds.